Author: Editor

Sundar Jagannath, MD of Icahn School of Medicine at Mount Sinai discusses what physicians should be aware of when sequencing agents in multiple myeloma treatment. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Sundar Jagannath, MD of Icahn School of Medicine at Mount Sinai explains how personalized medicine will impact the treatment of multiple myeloma at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Howard Hochster, MD of Yale Cancer Center discusses the impact of immunotherapy for the treatment of gastric and GE junction cancers at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Howard Hochster, MD of Yale Cancer Center discusses whether or not stage III colon cancer patients should be treated with either 3 months or 6 months of FOLFOX therapy. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Howard Hochster, MD of Yale Cancer Center discusses new peri-operative treatment regimens for resectable gastric and GE junction cancers at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Howard Hochster, MD of Yale Cancer Center gives an overview of treatments for BRAF-mutated positive colorectal cancer patients at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Patricia Goldsmith, CEO of CancerCare discusses the new data on patient-focused initiatives presented at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Patricia Goldsmith, CEO of CancerCare discusses the tools that cancer patients should have as they progress on their journey. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Patricia Goldsmith, CEO of CancerCare discusses the financial programs that are provided by CancerCare for cancer patients to help with treatment and cancer care costs. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Richard M. Goldberg, MD, FAnnual Meeting of West Virginia University Cancer Institute discusses the use of pembrolizumab in tumor-agnostic MSI-high patients at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Richard M. Goldberg, MD, FAnnual Meeting of West Virginia University Cancer Institute gives an overview of the promising data presented at Annual Meeting on resected biliary tract cancer (cholangiocarcinoma). This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Richard M. Goldberg, MD, FAnnual Meeting of West Virginia University Cancer Institute discusses the optimal duration of therapy for a stage III colon cancer patient. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Richard M. Goldberg, MD, FAnnual Meeting of West Virginia University Cancer Institute explains how he defines a high-risk from a low-risk stage III colon cancer patient at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Robert Figlin, MD of Samuel Oschin Comprehensive Cancer Institute explains the use of checkpoint inhibitors is changing the treatment standards for renal cell carcinoma. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Robert Figlin, MD of Samuel Oschin Comprehensive Cancer Institute discusses his thoughts on sequencing when treating patients with metastatic renal cell carcinoma. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Robert Figlin, MD of Samuel Oschin Comprehensive Cancer Institute explains how he stratifies metastatic RCC patients to choose the most appropriate treatments at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Robert Figlin, MD of Samuel Oschin Comprehensive Cancer Institute gives an overview of the promising data on renal cell carcinoma presented at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Robert Figlin, MD of Samuel Oschin Comprehensive Cancer Institute discusses the future impact of new therapies for renal cell carcinoma treatment at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Neelima Denduluri, MD of Virginia Cancer Specialists gives an overview of the phase III study, the APHINITY trial, and its impact on future clinical practice and the treatment of adjuvant breast cancer. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Neelima Denduluri, MD of Virginia Cancer Specialists gives an overview of the new approaches in treatment of breast cancer at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Neelima Denduluri, MD of Virginia Cancer Specialists discusses how CDK 4/6 inhibitors are changing the treatment of breast cancer at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Neelima Denduluri, MD of Virginia Cancer Specialists explains how the results of the MONARCH-2 study will change future treatment of breast cancer at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Nancy Dawson, MD of Lombardi Cancer Center at Georgetown University Hospital discusses the difference in side effects between abiraterone and chemotherapy at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Nancy Dawson, MD of Lombardi Cancer Center at Georgetown University Hospital discusses how physicians should treat hormone-sensitive advanced prostate cancer patients. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Nancy Dawson, MD of Lombardi Cancer Center at Georgetown University Hospital gives an overview of the STAMPEDE study, which focuses on the use of abiraterone acetate in the treatment of prostate cancer. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Nancy Dawson, MD of Lombardi Cancer Center at Georgetown University Hospital discusses her thoughts on the LATITUDE study for prostate cancer, which was presented at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Nevena Damnjanov, MD of Abramson Cancer Center at Penn Presbyterian, University of Pennsylvania discusses how she reliably identifies subgroups for targeted therapies in HCC at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Nevena Damnjanov, MD of Abramson Cancer Center at Penn Presbyterian, University of Pennsylvania gives an overview of what she learned from the phase III trial, Checkpoint 459, on the use of nivolumab in advanced HCC. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Nevena Damnjanov, MD of Abramson Cancer Center at Penn Presbyterian, University of Pennsylvania explains how new agents being studied will be integrated into clinical practice for the treatment of advanced HCC at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Nevena Damnjanov, MD of Abramson Cancer Center at Penn Presbyterian, University of Pennsylvania discusses the use of lenvatinib in the first line setting for the treatment of hepatocellular carcinoma. This was recorded at the 2917 Annual Meeting Annual Meeting in Chicago, IL.

Barbara Ann Burtness, MD of Yale Cancer Center gives an overview of the LUX Head and Neck 2 trial, which was presented at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Barbara Ann Burtness, MD of Yale Cancer Center explains the use of bevacizumab plus chemotherapy for the treatment of patients with metastatic head and neck cancer. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Barbara Ann Burtness, MD of Yale Cancer Center explains whether or not patients with head and neck cancers should be tested for PD-L1. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Barbara Ann Burtness, MD of Yale Cancer Center discusses how immunotherapies are being integrated into head and neck cancer treatments at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Phil Bonomi, MD of Rush University Medical Center discusses how immunotherapies are being integrated into the treatment of small cell lung cancer and mesothelioma at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Phil Bonomi, MD of Rush University Medical Center discusses whether or not MET inhibitors are effective in the treatment of metastatic non-small cell lung cancer. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Noa Biran, MD of John Theurer Cancer Center discusses which novel agents to use in the treatment of multiple myeloma. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Noa Biran, MD of John Theurer Cancer Center discusses personalized medicine for the treatment of multiple myeloma patients at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Noa Biran, MD of John Theurer Cancer Center explains how immunotherapies are being integrated into treatment of multiple myeloma at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Noa Biran, MD of John Theurer Cancer Center discusses induction therapy for treatment of multiple myeloma patients at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

J. Thaddeus Beck, MD, FACP of Highlands Oncology Group explains whether or not the Watson for Clinical Trials Matching tool will increase work flow at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

J. Thaddeus Beck, MD, FACP of Highlands Oncology Group discusses how the Watson for Clinical Trials Matching tool work at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

J. Thaddeus Beck, MD, FACP of Highlands Oncology Group discusses the design of the Watson for Clinical Trials Matching tool at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Lyudmila Bazhenova, MD of UC San Diego Health explains whether or not ALK inhibitors can be sequenced in clinical practice at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Lyudmila Bazhenova, MD of UC San Diego Health discusses what physicians should expect when treating ALK positive lung cancer patients with ALK inhibitors at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Lyudmila Bazhenova, MD of UC San Diego Health explains how to choose one ALK inhibitor over the others at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Lyudmila Bazhenova, MD of UC San Diego Health discusses the reliability of the ALK biomarker and whether or not physicians can trust the test in their clinical practice. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Aref Al-Kali, MD of Mayo Clinic discusses some of the challenges in treating elderly acute myeloid leukemia patients at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Aref Al-Kali, MD of Mayo Clinic discusses the use of the Leukostat test in clinical practice, which was approved with midostaurin at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Aref Al-Kali, MD of Mayo Clinic discusses the approval of midostaurin for FLT3+ AML patients. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.